Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries

(

TEVA

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.9%. By the end of trading, Teva Pharmaceutical Industries rose $3.39 (6.9%) to $52.84 on heavy volume. Throughout the day, 13,627,418 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6,865,300 shares. The stock ranged in a price between $49.60-$52.94 after having opened the day at $49.60 as compared to the previous trading day's close of $49.45. Other companies within the Health Care sector that increased today were:

Reliv' International

(

RELV

), up 20.7%,

OncoMed Pharmaceuticals

(

OMED

), up 15.9%,

Actinium Pharmaceuticals

(

ATNM

), up 14.2% and

NovaBay Pharmaceuticals

(

NBY

), up 13.6%.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $46.5 billion and is part of the drugs industry. Shares are up 23.4% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front,

Prana Biotechnology

(

PRAN

), down 71.6%,

Momenta Pharmaceuticals

(

MNTA

), down 16.9%,

MannKind Corporation

(

MNKD

), down 16.8% and

Fate Therapeutics

(

FATE

), down 13.5%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.